Premium
Prevention therapeutics of dementia
Author(s) -
Schneider Lon S.
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2007.11.005
Subject(s) - drug development , dementia , clinical trial , medicine , guideline , disease , intensive care medicine , drug , drug discovery , risk analysis (engineering) , pharmacology , bioinformatics , pathology , biology
In the absence of effective drugs for Alzheimer's disease (AD) and a validated roadmap or guideline for drug development, it is important to consider some of the limitations currently hampering AD drug development and some general principles for moving forward. This paper will address current barriers to developing drugs for AD, and offer new considerations for accelerating drug discovery, development, and clinical trials.